25 Jul 2024
08:00 CEST |
GOLDEN ENERGY OFFSHORE SERVICES ASA |
GEOS Commercial update and New Contract on Large Size PSV Energy Swan
|
60101030 Oil Equipment and Services |
Non-regulatory press releases |
25 Jul 2024
08:00 CEST |
EURONAV |
Euronav kondigt Q2 2024 resultaten aan op donderdag 8 augustus 2024
|
50206030 Marine Transportation |
Other subject |
25 Jul 2024
08:00 CEST |
RELX |
RELX 2024 Interim Results Announcement 25 July 2024
|
40301030 Publishing |
Commercial results |
25 Jul 2024
08:00 CEST |
NOVACYT |
Half Year Trading Update
|
20102010 Medical Equipment |
Legal |
25 Jul 2024
08:00 CEST |
GALIMMO |
Information financière de Galimmo SCA au 30 juin 2024
|
35101010 Real Estate Holding and Development |
Income |
25 Jul 2024
08:00 CEST |
EURONAV |
Euronav announces Q2 2024 results on Thursday 8 August 2024
|
50206030 Marine Transportation |
Other subject |
25 Jul 2024
08:00 CEST |
NOVACYT |
Rapport semestriel d'activité
|
20102010 Medical Equipment |
Legal |
25 Jul 2024
08:00 CEST |
SAFE |
SAFE - Entrée en négociation exclusive avec SpineUp - Accélération de la feuille de route
|
20102015 Medical Supplies |
- |
25 Jul 2024
07:37 CEST |
RENAULT |
Communication about the availability of 2024 H1 financial report
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:37 CEST |
RENAULT |
Communication de mise à disposition du rapport financier du premier semestre 2024
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:35 CEST |
RENAULT |
Financial report - 2024 H1
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:35 CEST |
RENAULT |
Rapport financier semestriel - S1 2024
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:32 CEST |
RENAULT |
Nissan’s contribution to Renault Group’s second quarter 2024 earnings
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:32 CEST |
RENAULT |
Contribution de Nissan aux résultats de Renault Group au titre du deuxième trimestre 2024
|
40101020 Automobiles |
Other subject |
25 Jul 2024
07:30 CEST |
JCDECAUX SE |
JCDecaux: H1 2024 results
|
40301020 Media Agencies |
Sales |
25 Jul 2024
07:30 CEST |
NORSK TITANIUM AS |
Norsk Titanium Awarded Initial Defense Market Production Contract
|
55102015 Metal Fabricating |
Non-regulatory press releases |
25 Jul 2024
07:30 CEST |
ACCOR |
First half 2024: Solid performances in line with growth targets
|
40501025 Hotels and Motels |
General meeting / Board Meeting |
25 Jul 2024
07:30 CEST |
SANOFI |
Communiqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevées
|
20103015 Pharmaceuticals |
Other subject |
25 Jul 2024
07:30 CEST |
GETLINK SE |
Getlink SE: Half-Year 2024 Results: Robust Half-Year Results, Annual EBITDA Guidance Confirmed
|
50206020 Railroads |
Other subject |
25 Jul 2024
07:30 CEST |
BOUSSARD GAVAUDAN HOLD LTD GBP |
BGHL (GBP): NAV(s)
|
30204000 Closed End Investments |
Other subject |
25 Jul 2024
07:30 CEST |
MOTORK PLC |
MotorK Reports Robust Performance for H1 2024
|
10101015 Software |
Commercial results |
25 Jul 2024
07:30 CEST |
NICOX S.A. |
Nicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de phase 3 Denali sur NCX 470
|
20103015 Pharmaceuticals |
Other subject |
25 Jul 2024
07:30 CEST |
JCDECAUX SE |
JCDecaux : Résultats du 1er semestre 2024
|
40301020 Media Agencies |
Sales |
25 Jul 2024
07:30 CEST |
BOURSE DIRECT |
Bourse Direct : Résultats consolidés du 1er semestre 2024. Produit net bancaire consolidé en hausse de 15,8%, Résultat d’exploitation consolidé en hausse de 24,7%, Accélération du recrutement de nouveaux comptes.
|
30202015 Investment Services |
Income |
25 Jul 2024
07:30 CEST |
ACCOR |
Premier semestre 2024 : Des performances solides alignées avec les objectifs de croissance
|
40501025 Hotels and Motels |
General meeting / Board Meeting |
25 Jul 2024
07:30 CEST |
AALBERTS N.V. |
Aalberts N.V.: Aalberts delivers 15% EBITA margin in challenging markets
|
50202020 Electronic Equipment: Control and Filter |
Other subject |
25 Jul 2024
07:30 CEST |
GETLINK SE |
Getlink SE : Résultats du 1er semestre 2024 : Résultats semestriels robustes, guidance d’EBITDA annuel confirmée
|
50206020 Railroads |
Other subject |
25 Jul 2024
07:30 CEST |
SANOFI |
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
|
20103015 Pharmaceuticals |
Other subject |
25 Jul 2024
07:30 CEST |
FORSEE POWER |
Forsee Power Announces Half-Year Sales of €84.4 Million, Up +7% From H1 2023
|
50202010 Electrical Components |
Sales |
25 Jul 2024
07:30 CEST |
Boussard Gavaudan |
BGHL (EUR): NAV(s)
|
30204000 Closed End Investments |
Other subject |
25 Jul 2024
07:30 CEST |
FORSEE POWER |
Forsee Power annonce un chiffre d'affaires semestriel de 84,4 M€, en croissance de +7% par rapport au S1 2023
|
50202010 Electrical Components |
Sales |
25 Jul 2024
07:30 CEST |
NICOX S.A. |
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
|
20103015 Pharmaceuticals |
Other subject |
25 Jul 2024
07:30 CEST |
OBIZ S.A. |
Chiffre d'affaires consolidé de 58,6 M EUR au 1er semestre 2024, en forte progression de +207% - Objectifs 2024 confirmés
|
10101020 Consumer Digital Services |
Legal |
25 Jul 2024
07:01 CEST |
BE Semiconductor Industries N.V. |
BE Semiconductor Industries N.V. Announces Q2-24 Results
|
10102010 Semiconductors |
Other subject |
25 Jul 2024
07:00 CEST |
EURAZEO SE |
BONNE EXÉCUTION DU PLAN STRATÉGIQUE : CROISSANCE DYNAMIQUE DE LA GESTION D’ACTIFS ET RÉALISATIONS EN HAUSSE AU PREMIER SEMESTRE 2024
|
30202010 Asset Managers and Custodians |
General meeting / Board Meeting |
25 Jul 2024
07:00 CEST |
EURAZEO SE |
GOOD EXECUTION OF STRATEGIC PLAN: DYNAMIC ASSET MANAGEMENT GROWTH AND PICK-UP IN REALIZATIONS IN H1 2024
|
30202010 Asset Managers and Custodians |
General meeting / Board Meeting |
25 Jul 2024
07:00 CEST |
STMICROELECTRONICS |
STMicroelectronics annonce ses résultats financiers du deuxième trimestre 2024
|
10102010 Semiconductors |
Commercial results |
25 Jul 2024
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
25 Jul 2024
07:00 CEST |
IPSEN |
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
|
20103015 Pharmaceuticals |
Commercial results |
25 Jul 2024
07:00 CEST |
CTP NV |
CTP Signs Another TSL Sector Client as Trako Team Takes Almost 10,000 sqm at Warsaw North
|
35101010 Real Estate Holding and Development |
News contracts |
25 Jul 2024
07:00 CEST |
TGS ASA |
TGS - Ex dividend of NOK 1.51 per share today
|
60101030 Oil Equipment and Services |
Ex Date |
25 Jul 2024
07:00 CEST |
INNATE PHARMA |
Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 10 juillet 2024
|
20103010 Biotechnology |
Other subject |
25 Jul 2024
07:00 CEST |
STMICROELECTRONICS |
STMicroelectronics Reports 2024 Second Quarter Financial Results
|
10102010 Semiconductors |
Commercial results |
25 Jul 2024
07:00 CEST |
IPSEN |
Ipsen publie de solides résultats pour le premier semestre 2024, progresse sur ses lancements et revoit à la hausse ses objectifs pour l’exercice en cours
|
20103015 Pharmaceuticals |
Commercial results |
25 Jul 2024
07:00 CEST |
ARCADIS |
Arcadis Q2 and Half Year 2024 Results: Continued growth and improved operating margin as 2024-2026 strategy implementation commenced
|
50101015 Engineering and Contracting Services |
Commercial results |
25 Jul 2024
07:00 CEST |
INNATE PHARMA |
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
20103010 Biotechnology |
Other subject |
25 Jul 2024
06:59 CEST |
DASSAULT SYSTEMES |
Dassault Systèmes: Second Quarter 2024 Results in Line With Preliminary Announcement - Non-IFRS Diluted EPS up 10% in the First Half
|
10101015 Software |
Commercial results |
25 Jul 2024
06:59 CEST |
DASSAULT SYSTEMES |
Dassault Systèmes : deuxième trimestre 2024 conforme à l’annonce préliminaire - Hausse de 10% du BNPA non-IFRS au premier semestre
|
10101015 Software |
Commercial results |
25 Jul 2024
06:58 CEST |
DASSAULT SYSTEMES |
Dassault Systèmes : Eisai sélectionne la solution Clinical Data Studio de Medidata pour améliorer et moderniser l’efficacité des essais cliniques et l’expérience des patients
|
10101015 Software |
News contracts |
25 Jul 2024
06:58 CEST |
IPSEN |
Ipsen et Day One concluent un accord exclusif de licence hors États-Unis pour commercialiser le tovorafénib contre la forme la plus courante de tumeur cérébrale chez l’enfant
|
20103015 Pharmaceuticals |
- |